Background {#Sec1}
==========

Nosocomial infections represent the main non-cardiac complication after cardiovascular surgery and are associated with substantial morbidity, increased mortality, prolonged hospitalization and, eventually, economic burden \[[@CR2], [@CR3]\]. Respiratory tract infections account for more than half of all nosocomial infections after open heart surgery followed by surgical site infections and bloodstream infections (BSI) with a prevalence of approximately 20% \[[@CR4]\]. Patients with BSI have a 4.2-fold increased risk of death, compared with non-infected patients \[[@CR5]\]. Environmental contamination could be responsible of nosocomial infection acquisition and diffusions of multi drug resistance microorganisms (MDR) \[[@CR6], [@CR7]\]. Current guidelines highlight the importance of rapid administration of the most appropriate antimicrobial treatment to improve the survival of patients with suspected BSI and sepsis \[[@CR8]\]. This is of special importance in respect of the problem of the ongoing antimicrobial resistance. The "gold standard" for the diagnosis of BSI is blood culture (BC) with pathogen identification and consecutive drug susceptibility testing. However, this process regularly requires at least 24 to 72 h. Sensitivity of BC is low due to uncultivable or fastidious microorganisms, polymicrobial or invasive fungal infections, or administration of anti-infectives prior to blood sampling \[[@CR9]\]. Lee et al. reported that 73% of pathogens were detected with the first blood cultures, 90% with two, 98% with three, and 99.8% with four different consecutive blood cultures \[[@CR10]\]. In addition, discrimination between infection and potential contamination is sometimes difficult. Thus, there is an urgent need to establish a rapid, sensitive, and specific method for detection of bacterial and fungal pathogens to improve management of patients with suspected BSI. PCR-based technologies have emerged over the last two decades and could represent an appropriate diagnostic tool in terms of sensitivity and speed of pathogen detection, in particular in life-threatening infections.

The LightCycler® SeptiFast (SF) is a multi-pathogen probe-based real-time PCR system targeting DNA sequences of 25 commonly observed bacteria and fungi present in blood samples within a few hours. However, data about the impact of PCR-based diagnostics on clinical decision-making process and modification of empirical antimicrobial therapy are very limited. A recently published prospective randomized trial demonstrated that in addition to a reduction in the time required for initial pathogen identification, the use of PCR was clearly able to reduce the time required for therapy modification from 38 to 19 h, however without reaching statistical significance \[[@CR11]\]. Currently, there are no data about the accuracy and the impact of PCR based detection of BSI in patients undergoing cardiac surgery. Therefore, the aim of our study was to compare the performance of SF with conventional BC system in patients suspected of having BSI after cardiothoracic surgery.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

In this retrospective observational study, data were collected between January 2009 and February 2013 on all consecutive patients with SF at our Intensive Care Unit (ICU), Department of Thoracic and Cardiovascular Surgery, West German Heart Centre Essen, Germany, in our institutional database. The diagnosis of the suspected BSI was made by clinical judgment by the treating physicians on basis of the occurrence of systemic inflammatory response syndrome (SIRS)/Sepsis criteria \[[@CR8]\]. The decision of using SF was made either by the treating physicians or the infectious disease specialists. Data analysis was performed after the collection period. The study was approved by the Institutional Review Board according to the Declaration of Helsinki. All of the patients had previously granted permission for use of their medical records for research purposes. This written informed consent was obtained within the preoperative surgical written and verbal information conversation.

Patients were considered for inclusion in the study only if the met the following criteria:(I)Suspected bacterial or fungal BSI(II)Collection of paired blood samples for SF and at least two sets of BCs (two aerobic and two anaerobic bottles) from a peripheral vein or a central venous line at the same time point (within two hours)

The BC and SF results were compared separately by positivity of samples and by detected species of microorganisms/isolates.

Blood cultures {#Sec4}
--------------

Blood samples (at least two pairs of aerobic and anaerobic BC bottles, volume of 8--10 mL each) were collected by sterile venipuncture or from a central venous catheter (CVC) after disinfection of the connector and inserted into aerobic and anaerobic bottles and were sent to the laboratory. Samples then were incubated into the Bactec 9240 Plus (Becton Dickinson, Heidelberg, Germany), an automated microbial detection platform based on the colorimetric detection of CO~2~ produced by growing microorganisms. BC bottles were incubated up to seven days. In case of a positive signal on the Bactec instrument, 10 μL blood from aerobic blood culture was plated onto chocolate agar, blood agar, MacConkey agar, chromogenic yeast medium, and, if anaerobic bottle were positive, additionally onto two solid anaerobic media (Beerens and Schaedler agar; all from Oxoid, Wesel, Germany). Identification and susceptibility testing was performed according to the EUCAST (European Committee on Antimicrobial Susceptibility Testing) standard using the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry VITEK MS, the VITEK2 (both bioMérieux, Nürtingen, Germany) and WalkAway MicroScan (Beckman Coulter, Krefeld, Germany) \[[@CR12]\].

SeptiFast {#Sec5}
---------

The LightCycler® SeptiFast test M Grade (Roche Molecular Systems, Mannheim, Germany) is an in vitro nucleic acid amplification test for the detection of bacterial as well as fungal DNA in human blood. It allows the identification of 25 bacterial and fungal species (see Table [1](#Tab1){ref-type="table"}), being responsible for approximately 90% of all bloodstream infections. SF is the first real-time PCR-based system to be awarded a Conformité Européenne (CE) mark for pathogen detection and identification in suspected bloodstream infection. The analytical sensitivity of the assay, as indicated by the manufacturer, is between three and 100 colony forming units (CFU)/ml, depending on the microorganism. Following the manufacturer's instructions, DNA was extracted and was amplified by the LightCycler® in three individual reactions (Gram-positive bacteria, Gram-negative bacteria, and fungi). To exclude false-negative results the test includes an internal control, provided by the SeptiFast kit. PCR products were simultaneously detected by fluorescence and melting temperature analysis, using specific hybridization probes and identification software.Table 1Analytical spectrum of the LightCycler® SeptiFast testGram-positive bacterial speciesGram-negative bacterial speciesFungal species*Staphylococcus aureusEscherichia coliCandida albicansStaphylococcus epidermidisKlebsiella pneumoniaeCandida tropicalisStaphylococcus haemolyticusKlebsiella oxytocaCandida parapsilosisStreptococcus pneumoniaeSerratia marcescentsCandida kruseiStreptococcus pyogenesEnterobacter cloacae, Enterobacter aerogenesCandida glabrataStreptococcus agalactiaeProteus mirabilisAspergillus fumigatusStreptococcus mitisPseudomonas aeruginosaEnterococcus faeciumAcinetobacter baumanniiEnterococcus faecalisStenotrophomonas maltophilia*For coagulase-negative staphylococci and streptococci, a semiquantitative analytical cut-off value has been set by the manufacturer for distinguishing between true pathogens and contaminants from the skin flora

Discrimination between infection and contamination in BC {#Sec6}
--------------------------------------------------------

Coagulase-negative staphylococci (CoNS), *Streptococcus* spp., *Corynebacterium* spp., or *Bacillus* spp. are frequent contaminants of BCs. To discriminate between true BSI and contamination, an algorithm based on a previous study was applied. A true BSI was considered if the patient has at least three SIRS criteria or two SIRS criteria and a CVC or other prosthetic material \[[@CR13]\]. Positive findings for fungi were interpreted according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group diagnostic classification of fungal infections \[[@CR14]\].

Discrimination between infection and contamination in SF {#Sec7}
--------------------------------------------------------

Isolates identified by PCR were considered to be pathogens or contaminants using a modified algorithm, combining microorganism pathogenicity, interpretation of blood culture results, and clinical, laboratory, and microbiological data \[[@CR15]\]. The threshold of the SeptiFast software, based on the bacterial DNA amount, excluded CoNS and streptococci from the positive results and considered them contaminants. Fungal pathogens were categorized as described above.

Statistical analysis {#Sec8}
--------------------

Statistical analyses were performed with SPSS Statistics 19 (IBM, Chicago, IL). Continuous data were expressed as median ± 95% confidence interval (CI); categorical data were expressed as percentage. Comparisons between two groups were carried out using unpaired Student's t-test for normally or the Mann-Whitney Rank Sum Test for non-normally distributed data. Multiple groups were compared with ANOVA. Univariate analysis was performed on the quantitative variables using the Student t-test or Mann-Whitney test and on the qualitative variables using the Chi^2^ test of Fisher's exact test.

To measure the sensitivity and specificity of laboratory and clinical data at different cut-off values, a conventional receiver operating characteristic (ROC) curve was generated. All variables showing a *p*-value of less than 0.1 between the two groups using Student t-test, Mann-Whitney test, Chi^2^ test of Fisher's exact test were selected for ROC analyses. The optimal cut-off concentration was defined by the highest Jouden index (J = sensitivity + specificity -- 1). Statistical significance was assumed for a *p*-value \< 0.05.

Results {#Sec9}
=======

During the study period, 279 matched blood samples from 169 patients suspected of having BSI were analyzed with conventional BC and SF. Out of these, 78% (132/169) were under antibiotic treatment at this time. Contaminants were significantly more frequent among blood cultures than SeptiFast (23 \[8.2%\] vs. 2 \[0.71%\], *p* \< 0.001).

After excluding contaminants, SF identified 47, while BC identified 49 episodes of BSI (χ^2^ = 0.05, *P* = 0.822). As illustrated in  Fig. [1](#Fig1){ref-type="fig"}, SF exclusively detected 36 pathogens that were missed by BC, whereas BC detected 39 pathogens in SF-negative individuals. Thus, 86 positive episodes of BSI were identified with the combination of both methods, being significantly higher than with SF or BC alone (χ^2^ = 10.86, *p* \< 0.001 for SF and χ^2^ = 12.35, *p* \< 0.001 for BC). BC analyses resulted in 51% sensitivity, 83% specificity, 46.7% positive predictive value (PPV), and 54.1% negative predictive value (NPV) whereas SF resulted in 51% sensitivity, 84% specificity, 46.4% PPV, and 54.4% NPV. s.Fig. 1Number of detected microorganisms classified as infection in PCR, blood culture

With BC, CoNS was the most frequently detected agent (13/49, 26.5%) followed by *E. faecium* (10/49, 20.4%) and *Candida* spp. (9/49, 18.4%). In contrast, the most frequently observed pathogen in SF was *Candida* spp. (9/47, 19.1%) followed by *Enterobacter* spp. (8/47) and *Klebsiella* spp. (7/49, 14.3%).

SF identified 7/33 (21%) Gram-positive bacteria, 28/35 (8%) Gram-negative, and 12/67 (67%) fungi, while BC identified 28/33 (85%), 12/35 (34%), and 9/18 (50%), respectively (Table [2](#Tab2){ref-type="table"}).

Gram-negative detection rate was significantly higher with SF than with BC (χ^2^ = 14.93; *p* \< 0.001), but for fungi, the difference to BC was not relevant (χ^2^ = 1.03; *p* = 0.3). In contrast, detection rate of Gram-positive bacteria was significantly higher with BC compared to SF (χ^2^ = 25,09; *p* \< 0.001).

SF identified 36 pathogens that were not found in BC, while BC detected 39 pathogens in SF negative specimens. Microbial strains exclusively identified by SF were: *E. coli* (*n* = 3), *Klebsiella* spp. (*n* = 6), *E. faecium* (*n* = 4), *Enterobacter* spp. (*n* = 7), *E. faecalis* (*n* = 1), *P. aeruginosa* (*n* = 3), *A. fumigatus* (*n* = 3), *C.* spp. (*n* = 6), *S. marcescens* (*n* = 3), *S. maltophilia* (*n* = 1). BC detected the following pathogens in SF negative samples: CoNS (*n* = 13), *E. faecium* (*n* = 10), *C. albicans* (*n* = 6), *S. marcesens* (*n* = 3), *Klebsiella* spp. (*n* = 2), *S. aureus* (*n* = 1), *E. coli* (*n* = 1), other *Streptococcus* spp. (*n* = 1), *E. faecalis* (*n* = 1), M. morganii (*n* = 1). Polymicrobial infections were observed in seven patients. Five episodes were detected by SF; while BC identified multiple agents in only four specimens.

Predictors for SF positivity {#Sec10}
----------------------------

Several variables of the patients with and without pathogen identification in SF and BC were compared, respectively (Table [3](#Tab3){ref-type="table"}). Whereas baseline demographics, gender, BMI, EuroScore-2 and SAPS and TISS on the day of admission on ICU as well as type of surgery did not differ between the two groups, patients with positive PCR were significantly younger than patients with negative PCR (57 years \[51.7--68.0\] vs. 68.0 \[64.3--70.0\], *p* = 0.01). In addition, prevalence of acute kidney Injury (AKI) with need for renal replacement therapy (RRT) was higher in SF positive patients (76% vs. 53%, *p* = 0.01).Table 2Detected microorganisms after exclusion of contaminationsNumber of isolatesPathogensTotalDetected by PCRDetected by BCPCR pos/BC posPCR pos/BC negPCR neg/BC posGram-positive bacteria337 (21%)28 (85%)2 (6%)5 (15%)26 (79%) *Staphylococcus aureus*21 (50%)2 (100%)1 (50%)0 (0%)1 (50%) *CoNS*130 (0%)13 (100%)0 (0%)0 (0%)13 (100%) *Streptococcus pneumoniae*000000 *Other Streptococcus spp.*10 (0%)1 (100%)0 (0%)0 (0%)1 (100%) *Enterococcus faecalis*32 (67%)2 (67%)1 (33%)1 (33%)1 (33%) *Enterococcus faecium*144 (29%)10 (71%)0 (0%)4 (29%)10 (71%)Gram-negative bacteria3528 (80%)12 (34%)6 (17%)22 (63%)7 (20%) *Escherichia coli*54 (80%)2 (40%)1 (20%)3 (60%)1 (20%) *Pseudomonas aeruginosa*55 (100%)2 (40%)2 (40%)3 (60%)0 (0%) *Enterobacter cloacea*88 (100%)1 (13%)1 (13%)7 (88%)0 (0%) *Klebsiella pneumonia*97 (78%)3 (33%)1 (11%)6 (67%)2 (22%) *Stenotrophomonas maltophilia*11 (100%)0 (0%)1 (100%)0 (0%)0 (0%) *Corynebacterium spp*0--0----0 *Morganella morganii*1--1 (100%)----1 (100%) *Serratia marcensens*63 (50%)3 (50%)0 (0%)3 (50%)3 (50%)Fungi1812 (67%)9 (50%)3 (17%)9 (50%)6 (17%) *Aspergillus fumigatus*33 (100%)0 (0%)0 (0%)3 (100%)0 (0%) *Candida albicans*159 (60%)9 (60%)3 (20%)6 (40%)6 (40%)*BC* blood cultures, *CoNS* coagulase-negative staphylococci, *neg* negative, *PCR* polymerase chain reaction (SeptiFast assay), *pos* positive, *spp.* species

Laboratory markers of inflammation differed significantly between groups: C-reactive protein (CRP) (21.7 mg/dl ±11.41 vs. 16.0 ± 16.9, *p* = 0.009), procalcitonin (PCT) (6.6 ng/ml \[2.7--16.4\] vs. 3.1 \[2.3--4.7\], *p* = 0.015) as well as interleukin 6 (IL-6) (235.0 pg/ml \[83.5--1582.2\] vs. 72.3 \[46.5--104.7\], *p* = 0.010) were significantly higher in patients with positive SF result. In contrast, patients with negative PCR had a significantly higher WBC than patients with positive PCR (14.0 \[13.0--15.0\] vs. 12 \[10.3--15.0\], *p* = 0.014).

Patients with proven BSI in SF suffered from a more complicated postoperative course with prolonged ICU stay compared to SF-negative patients (ICU stay \[days\]: 26.1 ± 16.2 vs. 19.4 ± 12.8, *p* = 0.019). Comparing patients with positive and negative BC, demographics, inflammatory markers and organ function did not differ whereas ICU-stay was longer in individuals with positive blood culture (16 days \[[@CR15]--[@CR19]\] vs. 18.5 \[14.0--26.2\], *p* = 0.044).

Using ROC analysis, IL-6 (AUC 0.836, sensitivity 78.6%, specificity 75.9% for a cut-off 184 pg/ml) as well as CRP (AUC 0.804, sensitivity 71.4%, specificity 75.9% for a cut-off 15.25 mg/dl) showed the best predictive values for positive SF results (Fig. [2](#Fig2){ref-type="fig"}). In contrast, PCT and leukocytes were associated with poor predictive capacity.Fig. 2Receiver operator characteristic (ROC) curve for the prediction of SF positivity.

Impact of SF on antimicrobial therapy {#Sec11}
-------------------------------------

In eight out of 37 cases with pathogens solitarily identified by SF (21.6%) microbiological diagnostic information led to therapy adaptations (Table [4](#Tab4){ref-type="table"}). Only one of these pathogens was detected by blood culture whereas the other seven remained undetected with conventional diagnostics. In three patients, detection of *A. fumigatus* in SF led to the addition of antifungal therapy with voriconazole, in another three patients therapy was escalated with fluconazole and caspofungin, respectively. In one patient, vancomycin was added due to *E. faecium* identification in SF. 50% of patients could be discharged home whereas four patients died during the further hospital course.Table 3Characteristics of patients with positive SF/BC result compared to those with negative SF/BC resultsPCR (SeptiFast)Blood cultureNegative *(n = 237)*Positive *(n = 42)P*-valueNegative *(n = 232)*Positive *(n = 47)P*-valueAge \[years\]68.0 \[64.3--70.0\]57 \[51.7--68.0\]**0.010**67 \[62.0--69.0\]69 \[59--69\]n.s.Male Gender \[n, %\]161 (68)30 (71)n.s.163 (70)28 (59)n.s.Operative Procedure \[n, %\] CABG47 (20)9 (21)n.s.46 (20)10 (21)n.s. Isolated AVR8 (3)1 (2)n.s.9 (4)0 (0)n.s. Isolated MVS5 (2)1 (2)n.s.4 (2)2 (4)n.s. Combined procedures101 (43)14 (33)n.s.99 (43)16 (34)n.s. Aortic surgery25 (11)4 (10)n.s.24 (10)5 (11)n.s. Thoracic transplant13 (5)4 (10)n.s.11 (5)6 (13)n.s. Others38 (16)9 (21)n.s.37 (16)8 (17)n.s.CPB time \[min.\]177.0 \[147.6--186.4\]149.0 \[116.6--207.8\]n.s.174.5 \[147.2--185.0\]161.0 \[139.7--198.9\]n.s.Euro-Score II \[%\]7.0 \[5.2--10.1\]8.8 \[2.9--21.0\]n.s.10.5 \[5.4--21.6\]n.s.TISS-28 on day of SF/BC19 \[17--21\]21 \[15--22\]n.s.19 \[17--21\]18 \[14--21\]n.s.SAPS on day of SF/BC32 \[31--34\]30 \[27--35\]n.s.32 \[31--33\]31 \[25--33\]n.s.Oxygenation \[mmHg/FiO~2~\]216.0 \[196.3--230.4\]240.0 \[210.2--269.5\]n.s.220 \[210.8--235.0\]214.5 \[195.7--282.7\]n.s.Heart frequency \[min^−1^\]80.0 \[80.0--90.0\]90.0 \[83.4--106.6\]n.s.90.0 \[80.0--90.0\]90 \[90.0--100.0\]n.s.Body temperature \[°C\]37.6 \[37.4--37.8\]37.6 \[37.1--37.9\]n.s.37.6 \[37.4--37.8\]37.6 \[37.1--38.0\]n.s.RRT \[n, %\]125 (53)31 (74)**0.01**129 (56)27 (57)n.s.Laboratory values Serum lactate \[mg/dl\]1.5 \[1.4--1.8\]1.4 \[1.1--1.9\]n.s.1.5 \[1.4--1.7\]1.4 \[1.1--2.5\]n.s. Bilirubin \[mg/dl\]0.9 \[0.7--1.0\]1.0 \[0.8--1.6\]n.s.0.9 \[0.7--1.0\]0.9 \[0.5--1.2\]n.s. Leucocytes \[/nl\]14.0 \[13.0--15.0\]12 \[10.3--15.0\]**0.014**14.0 \[13.0--14.0\]14.0 \[10.5--16.0\]n.s. Fibrinogen \[mg/dl\]464.0 \[430.0--496.7\]525.0 \[389.9--594.2\]n.s.472 \[433.8--503.9\]504 \[438.5--544.9\]n.s. CRP \[mg/dl\]14.4 \[13.3--15.4\]14.5 \[13.3--15.4\]**0.009**14.8 \[13.7--15.9\]15.2 \[13.2--19.7\]n.s. PCT \[ng/ml\]3.1 \[2.3--4.7\]6.6 \[2.7--16.4\]**0.015**3.4 \[2.5--4.9\]2.2 \[1.3--3.8\]n.s. IL-6 \[pg/ml\]72.3 \[46.5--104.7\]235.0 \[83.5--1582.2\]**0.010**90.9 \[61.7--144.3\]141.0 \[46.6--240.2\]n.s.ICU stay \[days\]16 \[15--19\]22 \[16--33\]**0.019**16 \[15--19\]18.5 \[14.0--26.2\]**0.044**Hospital stay \[days\]23 \[19--29\]38 \[25--59\]n.s.27 \[21--30\]28 \[20.7--42.7\]n.s.*AVR* Aortic valve replacement, *CABG* coronary artery bypass grafting, *CPB* Cardiopulmonary bypass, *CRP* C-reactive protein, *ICU* intensive care unit, *IL-6* interleukin 6, *LTX* lung transplant, *MVS* mitral valve surgery, *n.s.* not significant (*p* \> 0.05), *PCT* procalcitonin, *POD* postoperative day, *RRT* renal replacement therapy, *SAP* Simplified Acute Physiology Score, *TISS* Therapeutic Intervention Scoring System, *TVS* tricuspid valve surgeryTable 4Impact of SF on antimicrobial therapyNo.Age range, genderPOD, SurgeryIdentified pathogen in SFIdentified pathogen in BCInitial antimicrobial therapyAdjustment of therapyOutcome after adjustment of therapy*1*50--59, 153, CABG, AVR, MVS*Aspergillus fumigatus*--Meropenem, VancomycinEscalation with voriconazolesurvived*2*50--59, 138, LTX*Aspergillus fumigatus*--Meropenem, Vancomycin, FluconazoleEscalation with voriconazole, discontinuation of fluconazoledied*3*70--79, 2CABG, AVR, MVS, TVS*Aspergillus fumigatus*--Piperacilline/TazobactamEscalation with voriconazoledied*4*50--59, 118, Aortic surgery*Candida albicansCandida albicans*Ciprofloxacine, Vancomycin, ColistinEscalation with caspofungindied*5*60--69, 233, AVR, MVS*Candida albicans--*Meropenem, VancomycinEscalation with fluconazolesurvived*6*60--69, 147, AVR*Candida albicans--*Linezolid, ImipenemEscalation with caspofunginsurvived*7*70--79, 121. CABG, MVS, TVS*Enterococcus faeciumCoNS*Piperacilline/TazobactamEscalation with vancomycindied*8*20--29, 149. LTX*Pseudomonas aeruginosa--*Vancomycin, CeftazidimeEscalation with colistinsurvived*AVR* Aortic valve replacement, *BC* blood culture, *CABG* coronary artery bypass grafting, *CoNS* Coagulase-negative staphylococci, *LTX* lung transplant, *MVS* mitral valve surgery, *POD* postoperative day, *SF* SeptiFast, *TVS* tricuspid valve surgery. To ensure patient's anonymity, gender was discriminated in 1 and 2

Discussion {#Sec12}
==========

Our data demonstrate that the PCR-based SF test might represent a rational adjunct tool to the traditional BC method for rapid etiologic diagnosis of BSI in patients after cardiothoracic surgery. SF detects significantly more Gram-negative microorganisms than BC, whereas BC was superior regarding Gram-positive pathogens.

Early and reliable diagnosis of BSI and identification of bacteria and fungi is essential to initiate appropriate therapy in septic patients within one hour after sepsis as recommended by current guidelines \[[@CR8], [@CR16]\]. For decades, detection of pathogen microorganisms in patients with suspected BSI was mainly based on BC. However, this procedure per se has two intrinsic limitations: Firstly, this method is limited by the delay of 12--36 h for positive signaling and up to 72 for identification of the pathogen and the antimicrobial susceptibility profile. In addition, approximately 30% of pathogens remain undetected by BC and the time to positivity is longer for some fastidious bacteria, anaerobes, and fungi or under antimicrobial therapy \[[@CR17]\]. Thus, there is an urgent need to improve the diagnostic tools for an improved management of patients with BSI or sepsis. Molecular methods, in particular the LightCycler SF, offer distinct advantages over blood cultures, including increased sensitivity and rapid diagnosis and is intensively investigated in clinical studies \[[@CR9], [@CR18]\]. However, diagnostic accuracy and cost--effectiveness should be established before implementation in clinical practice.

A meta-analysis including a total of 34 studies enrolling 6012 patients with suspected sepsis reported a high specificity with a modest and highly variable sensitivity \[[@CR19]\]. Recent studies revealed a low sensitivity of the PCR method accompanied with a limited utility for the diagnosis of healthcare-associated BSI in critical care patients \[[@CR20]\]. In contrast, another study including 104 critically ill patients suffering from SIRS showed that in 25 cases (16.9%, *n* = 148) rapid identification of involved pathogens by multiplex-PCR led to adjustment of therapy \[[@CR21]\]. A randomized controlled trial enrolling 78 adults with suspected pulmonary or abdominal infection demonstrated a significant reduction in the time required for initial pathogen identification with SF compared with BC \[[@CR10]\]. Even in the context of an increasing number of MDR rapid detection of the respective microorganisms is essential \[[@CR22]\]. Taken together, the results about the usefulness of the SF for rapid detection of BSI in critical ill patients are divergent.

Patients after cardiothoracic surgery significantly differ from other cohorts: The use of cardiopulmonary bypass leads to a damage of the gastrointestinal mucosa, subsequent increased permeability, possible bacteremia, and the activation of a self-limited inflammatory response. The incidence of fungal infections especially in transplant recipients is, due to immunosuppression, higher than in the general ICU population. Commonly used biomarkers for bacterial infection might not work properly in the cardiothoracic population \[[@CR16], [@CR23]\].

In accordance with previous studies, the results of the present study demonstrate that SF, compared to BC, provided a better management of contaminants and a lower contamination rate \[[@CR24]\]. In respect of CoNS interpretation and discrimination in BC clinical judgment must be used due to a lack of objective criteria. In contrast, in SF an automated software is used to identify contaminants, which explains the lower rate of contaminants.

In accordance with recently published data, we observed a clear superiority of SF in detecting Gram-negative organisms compared to conventional BC \[[@CR25]\]. The reason for this discrepancy is unclear. Recent studies could demonstrate that the superiority of SF over BC is particularly observed in patients with severe sepsis \[[@CR26]\]. In our cohort, patients with Gram negative BSI had higher concentration of CRP, IL-6 and PCT as well as a higher incidence of AKI with need for RRT compared to those with Gram-positive pathogens. Therefore, it might be hypothesized that SF is superior in detecting Gram-negative pathogens particularly in critically ill patients with severe infections.

BSI caused by Gram-negative bacteria is associated with a 7-fold increased risk of early mortality after cardiac surgery, compared with no BSI \[[@CR5]\]. In contrast, BSI caused by Gram-positive bacteria other than *S. aureus* was only associated with a 2.2-fold increased risk of mortality \[[@CR27]\]. Therefore, the early detection of Gram-negative bacteria in SF is of tremendous clinical relevance and might help to reduce mortality.

Since invasive fungal infections with Aspergillus are frequently associated with high morbidity and mortality, in particular immunocompromised patients benefit from prompt initiation of anti-fungal therapy \[[@CR28]\]. However, the Surviving Sepsis Campaign does not recommend the routine use of empirical antifungals, based on the relatively low frequency of fungal causation of sepsis (∼5% of cases), although this is likely to rise. In our cohort of patients, a notably but not significant higher number of *Aspergillus* amplicons were detected by PCR as compared with BC. SF could improve patient outcome as a result of rapid and accurate fungi detection and the consecutive timely initiation of appropriate therapy \[[@CR29]\]. Hence, one important clinical impact of SF seems to be the identification of otherwise undetected fungal BSI.

However, SF was inferior to BC in detecting Gram-positive bacteria including *S. aureus,* representing an important pathogen associated with high mortality. CoNS are a major constituent of human skin commensal flora, which were once considered relatively apathogen and a likely contaminant. But in patients with foreign materials (e.g. prosthetic valves, pacemakers, intravascular catheters) these organisms, due to their propensity to form a biofilm and to display resistance to multiple antibiotics, have increasingly been recognized as a cause of clinically significant infections. Thus, due to the significant number of infections that would be missed, SF could not replace blood culture for the identification of bloodstream infections. In addition, in SF pathogen identification is restricted to the 25 tested microorganisms and, moreover, susceptibility testing is not possible. In respect of the ongoing problem of multi drug resistance susceptibility testing is of increasing importance \[[@CR30]\]. Therefore, SF cannot replace BC but represents an adjunct tool in combination with BC.

Even though in our study antimicrobial therapy was escalated due to the results of SF in eight patients, no de-escalation was done. As most of our patients were already on broad spectrum antibiotics and several blood cultures were drawn before choosing SF as diagnostic tool, empirical antibiotic therapy was considered to be adequate for most of the pathogens detected in SF and de-escalation was not done due to the lack of susceptibility testing.

Recent studies could demonstrate that use of new PCR based technologies in the management of septic patients lead to a significant reduction in treatment costs with a an average net saving of 9970 € per patient \[[@CR31]\]. This economic benefit is mainly based on shortening of intensive care unit stay and the use of fewer antibiotics. However, the costs of SeptiFast (approximately 200--300 USD) are high compared to Blood Culture (approximately 30 USD).

Mencacci investigated the predictive role of procalcitonin in patients with suspected sepsis for positive test results in BC and PCR and revealed an area under the curve of 0.927 for SF positivity \[[@CR32]\]. When applying a cut-off value of 0.37 ng/ml, the number of SF assays could be reduced by 53.9% with identifying 96.4% of pathogens. Leli et al. identified increased procalcitonin or white blood cells, fever \> 38 °C, and low serum albumin as independent predictors of positive SF results in blood samples taken within 12 h after the onset of fever in 285 patients \[[@CR33]\]. In our cohort, IL-6 as well as CRP was good predictors for SF positivity. Although PCT concentration are considered to be the gold standard of systemic inflammatory markers for diagnosis and evaluation of the treatment effectiveness, this marker only showed moderate predictive capabilities. The discrepancy could be due to the following: It is well established that aortic cross clamp and cardiopulmonary bypass related perioperative stress is associated with elevated PCT after cardiac surgery \[[@CR34]\]. Several studies showed a poor correlation between elevated PCT concentration and bacterial infections or sepsis after major cardiac surgery \[[@CR35]\]. Another aspect is that in our study 12 out of 47 positive SF results identified fungal pathogens. Thus, PCT as marker of bacterial infections is, anyway, not suitable for prediction of SF positivity in our cohort even more. Although the correlation of biomarkers and SF results are not very strong, in respect of the high costs of SF it might be helpful in the decision to perform SF or not.

Limitations {#Sec13}
===========

There are several potential limitations to this study. First, our study suffers from the general limitation of a single-center, retrospective investigation: the results may not be applicable to other clinical settings with different patient characteristics, resources, and laboratory procedures. In addition, due to the small number of specific pathogens, the power to detect a difference between the groups is limited.

In interpreting the results of this study heterogeneity in the methods of drawing blood samples for BC must be considered as a limitation. It could not be ensured that all collected samples complied with the guidelines for drawing blood samples for BC, what can affect both for sensitivity and specificity \[[@CR36]\].

A major limitation is the fact that there were no predefined criteria for performing PCR e.g. presence of more than two SIRS criteria. The algorithms used in this study to differentiate between contamination and infection of BC and SF were not evaluated in the cardiothoracic population. Therefore, the reliability of this algorithm in this setting is uncertain. However, as there is no published algorithm for cardiothoracic patients, we modified the originally published algorithm to incorporate specific characteristics of our patient's cohort e.g. the presence of prosthetic heart valves or other extracorporeal devices.

Due to the retrospective nature of our study we could not ensure that the same blood sample was used for SF and BC.

It has to be mentioned that the SF test is not available in the United States yet.

Conclusion {#Sec14}
==========

The PCR-based SF test might represent a valuable addition to the BC method for rapid etiologic diagnosis of bloodstream infections in patients after cardiothoracic surgery. This applies in particular for individuals with Gram-negative bacteremia. Since SF missed a certain number of Gram-positive pathogens, can only detect a limited number of pathogens and is unable to determine antibiotic susceptibility, it should always be used in conjunction with traditional blood culture methods.

AKI

:   Acute kidney injury

ANOVA

:   Analysis of variance

AUC

:   Area under the Curve

AVR

:   Aortic valve replacement

BC

:   Blood culture

BSI

:   Bloodstream infections

CABG

:   Coronary artery bypass grafting

CE

:   Conformité Européenne

CFU

:   Colony forming units

CI

:   Confidence interval

CoNS

:   Coagulase-negative staphylococci

CPB

:   Cardiopulmonary bypass

CRP

:   C-reactive protein

CVC

:   Central venous catheter

DNA

:   Deoxyribonucleic acid

ICU

:   Intensive Care unit

IL-6

:   Interleukin 6

LTX

:   Lung transplant

LVAD

:   Left ventricular assist device

MDR

:   Multi drug resistance microorganisms

MVS

:   Mitral valve surgery

NI

:   Nosocomial infections

NPV

:   Negative predictive value

PCR

:   Polymerase chain reaction

PCT

:   Procalcitonin

POD

:   Postoperative day

PPV

:   Positive predictive value

ROC

:   Receiver operating characteristic

RRT

:   Renal replacement therapy

SF

:   SeptiFast

SIRS

:   Systemic inflammatory response syndrome

spp.

:   species

TVS

:   Tricuspid valve surgery
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